Key result
Letters to the editor argue that the previously reported association between spironolactone and upper gastrointestinal bleeding is unproved due to confounding by comorbidities and concurrent medications.
Why the study?
Does spironolactone increase upper gastrointestinal events in patients with heart failure?
Does spironolactone increase upper gastrointestinal events in patients with heart failure?
Answers are grounded in this paper and cite their sources.
The causal relationship between spironolactone and upper gastrointestinal bleeding remains unproven due to significant confounding factors, suggesting clinical practice should not be altered.
EDITOR—The study reported by Verhamme et al has several noteworthy limitations.1 Firstly, the mortality benefit conferred by spironolactone therapy in heart failure has been shown only among patients with severe disease2 and hence, as the authors acknowledged, such patients are far more likely to be prescribed this therapy than patients with, for example, relatively asymptomatic echocardiographic evidence of impaired left ventricular function. Given …
No takes yet. Share an insight, caveat, or question.
Muhammad F. Dawwas (2006) conducted a letter in Upper gastrointestinal bleeding. Spironolactone was evaluated. Letters to the editor argue that the previously reported association between spironolactone and upper gastrointestinal bleeding is unproved due to confounding by comorbidities and concurrent medications.
Synapse has enriched 10 related papers. Consider them for comparative context: